HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark S Kaminski Selected Research

tositumomab I-131 (Bexxar)

2/2015Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.
8/2014R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.
7/2010131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.
6/2010Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
10/2005Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
2/2005131I-tositumomab therapy as initial treatment for follicular lymphoma.
3/2003Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
2/2002Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark S Kaminski Research Topics

Disease

15Lymphoma (Lymphomas)
02/2022 - 02/2002
15Non-Hodgkin Lymphoma (Lymphosarcoma)
11/2017 - 03/2002
13Neoplasms (Cancer)
11/2017 - 02/2002
9Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2019 - 02/2002
4Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2019 - 11/2013
2B-Cell Lymphoma (Lymphoma, B Cell)
11/2021 - 02/2016
2Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
01/2019 - 05/2014
2Hodgkin Disease (Hodgkin's Disease)
01/2019 - 01/2017
2Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
01/2018 - 12/2017
2Multiple Myeloma
07/2011 - 10/2009
1Body Weight (Weight, Body)
02/2022
1T-Cell Lymphoma (Lymphoma, T Cell)
12/2017
1Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
12/2017
1Fatigue
01/2017
1Sezary Syndrome (Sezary Erythroderma)
12/2016
1Mycosis Fungoides
12/2016
1Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
07/2014
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
07/2009
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
06/2005
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
06/2005

Drug/Important Bio-Agent (IBA)

8tositumomab I-131 (Bexxar)FDA Link
02/2015 - 02/2002
5Rituximab (Mabthera)FDA Link
01/2018 - 10/2013
5Biological ProductsIBA
11/2017 - 05/2011
4Vincristine (Oncovin)FDA LinkGeneric
01/2020 - 06/2010
4IodineIBA
01/2018 - 12/2004
4Bortezomib (Velcade)FDA Link
02/2015 - 10/2009
3Prednisone (Sone)FDA LinkGeneric
01/2019 - 06/2010
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2019 - 06/2010
2Proteins (Proteins, Gene)FDA Link
11/2021 - 11/2016
2Doxorubicin (Adriamycin)FDA LinkGeneric
01/2019 - 01/2018
2Amino AcidsFDA Link
01/2019 - 11/2016
2Dexamethasone (Maxidex)FDA LinkGeneric
07/2011 - 10/2009
2liposomal doxorubicin (Doxil)FDA Link
07/2011 - 10/2009
2Iodine-131IBA
06/2010 - 02/2002
2L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
07/2009 - 03/2003
1IceIBA
02/2022
1Phosphotransferases (Kinase)IBA
11/2021
1Immunoconjugates (Immunoconjugate)IBA
11/2021
1Leucine (L-Leucine)FDA Link
01/2019
1carboxyl radical (COO-)IBA
01/2019
1obinutuzumabIBA
01/2019
1acalabrutinibIBA
01/2019
1Proton-Translocating ATPases (ATPase, H+)IBA
01/2019
1Adenosine Triphosphatases (ATPase)IBA
01/2019
1Vacuolar Proton-Translocating ATPases (V-Type ATPase)IBA
01/2019
1Proteasome Endopeptidase Complex (Proteasome)IBA
12/2017
1ixazomibIBA
12/2017
1Transcription Factors (Transcription Factor)IBA
12/2017
1Proteasome InhibitorsIBA
12/2017
1Biomarkers (Surrogate Marker)IBA
11/2017
1Monomeric GTP-Binding ProteinsIBA
11/2016
1Mutant Proteins (Protein, Mutant)IBA
11/2016
1Proto-Oncogene Proteins c-bcl-2 (Proto Oncogene Proteins c bcl 2)IBA
02/2016
1LuciferasesIBA
01/2015
1Interleukin-4 (Interleukin 4)IBA
01/2015
1AntibodiesIBA
08/2014
1Anaplastic Lymphoma KinaseIBA
07/2014
1Antineoplastic Agents (Antineoplastics)IBA
05/2014
1EverolimusFDA Link
05/2014
1Histones (Histone)IBA
03/2014
1pidilizumabIBA
11/2013
1Lenalidomide (CC 5013)FDA Link
07/2011
1Protons (Proton)IBA
05/2011
1Radioisotopes (Radionuclides)IBA
07/2010
1AnthracyclinesIBA
06/2010
11-dodecylpyridoxal (PLD)IBA
10/2009

Therapy/Procedure

21Therapeutics
11/2021 - 02/2002
12Radioimmunotherapy
01/2018 - 03/2002
4Drug Therapy (Chemotherapy)
12/2017 - 02/2005
2Injections
02/2014 - 05/2011
1Drug Tapering
02/2022
1Aftercare (After-Treatment)
01/2018
1Salvage Therapy
01/2018
1Lymphatic Irradiation
01/2017
1Hematopoietic Stem Cell Transplantation
11/2013
1Stem Cell Transplantation
10/2013
1Transplantation
07/2009
1Organ Transplantation
07/2009